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 BRAF inhibitors are important antineoplastics. They work on the principle of inhibition 
of certain types of protein kinases and turned out to be very efficient for the treatment of 
melanoma. One of their disadvantages is relatively early onset of resistance; thus, it is important 
to look for new combinations of drugs that are already in use or work on the development of 
new structures with similar inhibition efficacy on melanoma cells. Encorafenib and its 
combination with binimetinib have been shown to be very promising drugs from the group of 
BRAF inhibitors, however, potential renal toxicity may be a therapeutic limitation. 
 This thesis was focused on the determination of in vitro cytotoxicity of encorafenib on 
different types of renal cells in three time intervals and on its comparison with two drug 
standards - amphotericin B and paracetamol. Three types of morphologically and functionally 
different kidney cells (PODO / TERT256, HK-2 and HEK293) were used for this purpose. The 
cytotoxic potential was measured by colorimetric method CellTiter 96® AQueous One Solution 
Cell Proliferation Assay, which is based on reduction of MTS reagent and cell viability was 
subsequently determined by the reduction rate. The obtained results are presented as IC50 values 
determined by analysis of the inhibition curves. The toxicity rate of the drug increased in the 
following order: HK2 < HEK293 < PODO/TERT256. This shows encorafenib to be the most 
toxic to podocyte cells, which may be related to the fact that BRAF is highly expressed in 
glomerular podocytes. As can be seen from the obtained data, encorafenib is also toxic to the 
other studied renal lines. Even so, encorafenib is a promising drug with good efficacy against 
several malignancies. 
 
